Peng, M.-H.; Huang, Y.-H.; Hsu, K.-H.; Tseng, J.-S.; Lee, P.-H.; Chen, K.-C.; Chang, G.-C.; Yang, T.-Y.
Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation. Cancers 2024, 16, 4174.
https://doi.org/10.3390/cancers16244174
AMA Style
Peng M-H, Huang Y-H, Hsu K-H, Tseng J-S, Lee P-H, Chen K-C, Chang G-C, Yang T-Y.
Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation. Cancers. 2024; 16(24):4174.
https://doi.org/10.3390/cancers16244174
Chicago/Turabian Style
Peng, Mu-Han, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Po-Hsin Lee, Kun-Chieh Chen, Gee-Chen Chang, and Tsung-Ying Yang.
2024. "Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation" Cancers 16, no. 24: 4174.
https://doi.org/10.3390/cancers16244174
APA Style
Peng, M.-H., Huang, Y.-H., Hsu, K.-H., Tseng, J.-S., Lee, P.-H., Chen, K.-C., Chang, G.-C., & Yang, T.-Y.
(2024). Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation. Cancers, 16(24), 4174.
https://doi.org/10.3390/cancers16244174
